MX9304638A - Composicion para tratar e inhibir las ulceras gastricas y duodenales. - Google Patents

Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Info

Publication number
MX9304638A
MX9304638A MX9304638A MX9304638A MX9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A
Authority
MX
Mexico
Prior art keywords
duodenal ulcers
treat
composition
inhibit gastric
gastric
Prior art date
Application number
MX9304638A
Other languages
English (en)
Inventor
Stephen Roth
Edward J Mcguire
Dennis H Langer
Original Assignee
Neose Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Pharm Inc filed Critical Neose Pharm Inc
Publication of MX9304638A publication Critical patent/MX9304638A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos y composiciones de oligosicaridos para tratar e inhibir las úlceras gástricas u duodenales, y a métodos para tratar e inhibir las ulceras gástricas y duodenales.
MX9304638A 1992-07-31 1993-07-30 Composicion para tratar e inhibir las ulceras gastricas y duodenales. MX9304638A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92251992A 1992-07-31 1992-07-31
US10448393A 1993-07-28 1993-07-28

Publications (1)

Publication Number Publication Date
MX9304638A true MX9304638A (es) 1994-05-31

Family

ID=26801599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304638A MX9304638A (es) 1992-07-31 1993-07-30 Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Country Status (3)

Country Link
US (4) US5620964A (es)
CN (1) CN1078074C (es)
MX (1) MX9304638A (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
DE69532293T2 (de) * 1994-12-01 2004-10-21 Seikagaku Kogyo Co Ltd Keratansulfatoligosaccharid-fraktion und sie enthaltendes medikament
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU710576B2 (en) * 1996-05-03 1999-09-23 Neose Technologies, Inc. Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
US6709656B1 (en) * 1996-06-10 2004-03-23 Thomas Boren Helicobacter pylori adhesin binding group antigen
EP0926154B1 (en) * 1996-07-23 2010-01-27 Seikagaku Corporation Novel lactosamine oligosaccharides and process for the preparation thereof
AU6584298A (en) * 1997-03-26 1998-10-20 Avant Immunotherapeutics, Inc. Carbohydrate antigens which immunoreact with polyclonal antisera against (h. pylori)
CA2286893A1 (en) * 1997-04-01 1998-10-08 Merieux Oravax 76 kda, 32 kda, and 50 kda helicobacter polypeptides and corresponding polynucleotide molecules
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
US20030124141A1 (en) * 1997-04-01 2003-07-03 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
AU7277798A (en) * 1997-05-01 1998-11-24 Cytel Corporation Use of sialyl galactosides and related compounds as anti-angiogenic agents
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6323008B1 (en) * 1997-08-14 2001-11-27 Neose Technologies, Inc. Methods for producing sialyloligosaccharides in a dairy source
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
EP1076716A1 (en) 1998-05-05 2001-02-21 McNeil Speciality Products Company Division of McNeil-PPC Inc. Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100460173B1 (ko) * 1998-12-11 2004-12-04 겐 코오포레이션 헬리코박터 파일로리 정착 억제제
AU6557299A (en) 1999-01-07 2000-07-13 Seikagaku Corporation Method for producing oligosaccharide, and novel oligosaccharide and pharaceutical composition containing the same
EP1074260B1 (en) 1999-07-21 2004-02-18 Seikagaku Corporation IL-12 Production inhibitor
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AUPQ275799A0 (en) 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
MXPA02008016A (es) * 2000-02-17 2002-11-29 American Home Prod Formulacion nutricional que contiene substancias prebioticas.
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
EP1411952B1 (en) * 2001-06-29 2009-04-22 Glykos Finland Oy Use of at least one glycoinhibitor substance against infectious diseases
FI20011403L (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
CA2455038A1 (en) * 2001-07-31 2003-02-13 Board Of Regents, University Of Texas System Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
EP1332759B1 (en) * 2002-02-04 2005-09-28 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical and nutritional compositions containing a di- or oligosaccharide as insulin secretion promoter
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EP2272522B1 (en) * 2002-06-28 2017-09-06 Nestec S.A. Therapeutic compositions for use in prophylaxis or treatment of diarrheas
OA13142A (en) * 2002-10-11 2006-12-13 Wyeth Corp Nutritional formulations containing synbiotic substances.
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US20050234448A1 (en) * 2004-03-19 2005-10-20 Mccarthy James Implantable bone-lengthening device
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2011512416A (ja) * 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
RU2410100C2 (ru) * 2009-03-30 2011-01-27 Александр Владимирович Диковский Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
IT1394503B1 (it) * 2009-04-06 2012-07-05 Inalco Spa Sali di 6'-sialillattosio e processo per la loro sintesi e per la sintesi di altri alfa-sialiloligosaccaridi.
US9578895B2 (en) 2010-08-23 2017-02-28 Epc (Beijing) Natural Products Co., Ltd. Rebaudioside A and stevioside compositions
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
US9795156B2 (en) * 2011-03-17 2017-10-24 E.P.C (Beijing) Plant Pharmaceutical Technology Co., Ltd Rebaudioside B and derivatives
NL2007931C2 (en) 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
CN122121857A (zh) * 2023-10-24 2026-05-29 帝斯曼知识产权资产管理有限公司 2’-岩藻糖基乳糖或3’-唾液酸乳糖用于减少微生物生长的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
ES2038669T3 (es) * 1986-09-18 1993-08-01 London School Of Pharmacy Innovations Ltd Formulacion farmaceutica.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
DE68915494T2 (de) * 1988-03-09 1995-01-05 Snow Brand Milk Prod Co Ltd Zubereitung mit verzögerter freigabe durch verwendung von alginaten.
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5348869A (en) * 1988-08-02 1994-09-20 Hoffmann-La Roche Inc. Process for producing tocopherols with spheroplasts of algae
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Also Published As

Publication number Publication date
US5753630A (en) 1998-05-19
US5514660A (en) 1996-05-07
CN1085430A (zh) 1994-04-20
US5620964A (en) 1997-04-15
US5883079A (en) 1999-03-16
CN1078074C (zh) 2002-01-23

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DK0480077T3 (da) Fremgangsmåde til fremstilling af carnosinsyre
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
DE69213231D1 (de) Zusammensetzung und methode zur verstärkung der sonnenbräunung
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
DK0981341T3 (da) Anvendelse af betulinsyrederivater til behandling og forebyggelse af melanom
NO996578L (no) Urokinase-inhibitorer
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
AP9200410A0 (en) Retroviral protease inhibitors.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
DK0701546T3 (da) Aromatiske acetylchlolinesteraseinhibitorer
ATE152725T1 (de) Silylierte acetylcholinesterase inhibitoren
SI1000034T1 (en) Substituted 6-alkylphenanthridines
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
DE69301904D1 (de) Zusammensetzung zur behandlung von keratinfasern
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
NO943765L (no) Aryloksybenzen-herbicidmidler
EP0612527A3 (en) Use of rhamnan, rhamnose or rhamnose oligomers for the treatment of gastric ulcer.
PT80152A (de) Methode zur behandlung des glaukoms vok
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
SE9200502D0 (sv) Novel antioxidants
NO961900D0 (no) Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
DE3583337D1 (de) Zusammensetzung zur behandlung von haemorroiden.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees